From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer

ONCOLOGY

Volumn 22, Issue 8, 2008, Pages 900-906

  Polascik, Thomas J ^a   Mayes, Janice M ^a   Mouraviev, Vladimir ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLADDER OBSTRUCTION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; CRYOABLATION; CRYOBIOLOGY; CRYONEEDLE; CRYOSURGERY; CRYOTHERAPY; FOCAL TARGETED CRYOABLATION; GLEASON SCORE; HEMIABLATION; HUMAN; IMPOTENCE; INCONTINENCE; NEEDLE; NONHUMAN; PATHOPHYSIOLOGY; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; RECTUM FISTULA; TEMPERATURE MEASUREMENT; THERAPY EFFECT; TUMOR VOLUME; URETHRA DISEASE; URETHRA FISTULA; URETHRA STRICTURE; URETHRAL PAIN; URETHRAL SLOUGHING; WHOLE GLAND CRYOABLATION; MALE; METHODOLOGY; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

CRYOSURGERY; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 55449109523     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Miller R, Cohen JK: Prostate cryosurgery, in Rukstalis DB, Katz AE (eds): Handbook of Urologic Cryoablation, pp 39-46. London, Informa UK Ltd, 2007.
2. Han KR, Belldegrun AS: Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int 93:14-18, 2004.
3. Mouraviev V, Polascik TJ: Update on cryosurgery for prostate cancer in 2006. Cur Opin Urol 16:152-156, 2006.
4. Han KR, Cohen JK, Miller RJ, et al: Treatment of organ confined prostate cancer with third generation cryostirgery: Preliminary multicenter experience. J Urol 170:1126-1130, 2003.
5. Prepelica KL, Okeke Z, Murphy A, et al: Cryosurgical ablation of the prostate: High risk patient outcomes. Cancer 103:1625-1630, 2005.
6. Baust JG, Gage AA, Klossner D, et al: Issues critical to the successful application of cryosurgical ablation of the prostate. Technol Cancer Res Treat 6:97-109, 2007.
7. Polascik TJ, Nosnik 1, Mayes JM, et al: Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology 70:117-121, 2007.
8. Gowardhan B, Greene D: Cryotherapy for the prostate: An in vitro and clinical study of two new developments; advanced cryoneedles and a temperature monitoring system. BJU Int 100:295-302, 2007.
9. Baust JG, Gage AA: The molecular basis of cryosurgery. BJU Int 95:1187-1191, 2005.
10. Clarke DM, Baust JM, Van Buskirk RG, et al: Addition of anticancer agents enhances freezing-induced prostate cancer cell death: Implications of mitochondrial involvement. Cryobiology 49:45-61, 2004.
11. KJossner DP, Robilotto AT, Clarke DM, et al: Cryosurgical technique: Assessment of the fundamental variables using human prostate cancer model systems. Cryobiology 55:189-199, 2007.
12. Gunder MJ: Cryosurgery in prostate carcinoma: Clinical evidence of immunostimulation of host versus tumor. Natl Cancer Inst Monogr 369, 1978.
13. Ablin R: An appreciation and realization of the concept of cryoimmunology, in Onik G, Rubinsky B, Watson G, et al (eds): Percutaneous Prostate Cryoablation, pp 136-154. St. Louis, Quality Medical Publishing, 1995.
14. Mouraviev V, Prochorov G, Ablin R: The combined cytoreductive cryoablation and immunochemotherapy for advanced prostate cancer (abstract 116). Abstracts of the 5th World Congress on Advances in Oncology, Rhodes, Greece, October 15-18. Int J Mol Med 6(suppl 1):202, 2000.
15. Hayakawa K, Yamashita T, Suzuki K, et al: Comparative immunological studies in rats following cryosurgery and surgical excision of 3-methylcholandirene-induced primary autochthonous tumors. Gann 73:462-469, 1982.
16. Hoffmann NE, Coad JE, Huot CS, et al: Investigation of the mechanism and the effect of cryoinmumology in the copenhagen rat. Cryobiology 42:59-68, 2001.
17. Udagawa M, Kudo-Saito C, Hasegawa G, et al: Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res 12:7465-7475, 2006.
18. Machlenkin A, Goldberger 0, Tirosh B, et al: Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin Cancer Res 11:4955-4961, 2005.
19. Shelley M, Wilt T, Coles B, et al: Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 18:1-16, 2007.
20. Donnelly BJ, Saliken JC, Ernst DS, et al: Prospective trial of cryosurgical ablation of the prostate: Five-year results. Urology 60:645-649, 2002.
21. Bahn DK, Lee F, Badalament R, et al: Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 60:3-11, 2002.
22. Wong WS, Chinn DO, Chinn M, et al: Cryosurgery as a treatment for prostate carcinoma: Results and complications. Cancer 79:963-974, 1997.
23. Jones J, Donnelly B, Pisters LL, et al: Primary prostate cryoablation: Results from 1198 patients tracked with the COLD registry (abstract 1773). AUA Annual Meeting Program Abstracts. J Urol 177(suppl):589, 2007.
24. Cresswell J, Asterling S, Chaudhary M, et al: Third-generation cryotherapy for prostate cancer in the UK: A prospective study of the early outcomes in primary and recurrent disease. BJU Int 97:969-974, 2006.
25. Mouraviev V, Nosnik 1, Sun L, et al: Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: A single-institution experience. Urology 69:311-314, 2007.
26. Robinson JW, Donnelly BJ, Saliken JC, et al: Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 60:12-18, 2002.
27. Ball AJ, Gambill B, Fabrizio MD, et al: Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: A short-term evaluation of five approaches from a single institution. J Endourol 20:723-731, 2006.
28. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149, 2004.
29. Cheng L, Jones TD, Pan CX, et al: Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 18:1022-1026, 2005.
30. Stamey TA, McNeal JE, Yemoto CM, et al: Biological determinants of cancer progression in men with prostate cancer. JAMA 281:1395-1400, 1999.
31. Stamey TA, Donaldson AN, Yemoto CE, et al: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidermiologic significance of annual changes. J Urol 160:2412-2417, 1998.
32. Noguchi M, Stamey TA, McNeal JE, et al: Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers. J Urol 170:459-463, 2003.
33. Renshaw AA, Richie JP, Loughlin KR, et al: Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Validation in a cohort of 434 patients. Am J Clin Pathol 111:641-644, 1999.
34. Rukstalis DB, Goldknopf JL, Crowley EM, et al: Prostate cryoablation: A scientific rationale for future modifications. Urology 60:19-25, 2002.
35. Epstein JI, Carmichael MJ, Partin AW, et al: Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: Pathogenetic and clinical implications. J Urol 151:1587-1592, 1994.
36. Mouraviev V, Mayes JM, Sun L, et al: Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 110:906-910, 2007.
37. Bostwick DG, Shan A, Qian J, et al: Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 83:1995-2002, 1998.
38. Mouraviev V, Sun L, Madden JF, et al: Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology 70:1141-1145, 2007.
39. Ohori M, Eastham JA, Koh H, et al: Is focal therapy reasonable in patients with early stage prostate cancer (CaP)-an analysis of radical prostatectomy (RP) specimens (abstract 1574). J Urol 175(suppl):507, 2006.
40. Lambert EH, Bolte K, Masson P, et al: Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology 69:1117-1120, 2007.
41. Bahn DK, Silverman P, Lee F Sr, et al: Focal prostate cryoablation: Initial results show cancer control and potency preservation. J Endourol 20:688-692, 2006.
42. ASTRO: Consensus Statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997.
43. Crawford ED, Barqawi A: Targeted focal therapy: A minimally invasive ablation technique for early prostate cancer. Oncology (Williston Park) 21:27-39 (incl discussion), 2007.
44. Ahmed HU, Pendse D, Illing R, et al: Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol 4:632-642, 2007.
45. Eggener SE, Scardino PT, Carroll PR, et al: Focal therapy for localized prostate cancer: A critical appraisal of rationale and modalities. J Urol 178:2260-2267, 2007.
46. Jones JS: Focal or subtotal therapy for early stage prostate cancer. Curr Treat Options Oncol 8:165-172, 2007.
47. Barqawi AB, Crawford ED: The current use and future trends of focal surgical therapy in the management of localized prostate cancer. Cancer J 13:313-317, 2007.
48. Onik G: Rationale for a "male lumpectomy," a prostate cancer targeted approach using cryoablation: Results in 21 patients with at least 2 years of follow-up. Cardiovasc Intervent Radial 31: 98-106, 2008.
49. D'Arnico AV: Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Williston Park) 15:1049-1059, 2001.
50. Cohen JK: Cryosurgery of the prostate: Techniques and indications. Rev Urol 6:S21-S26, 2004.
51. Roach MR, Hanks G, Thames HJ, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 15 965-974, 2006.